These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 15749666

  • 1. Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays.
    Zinzani PL, Dirnhofer S, Sabattini E, Alinari L, Piccaluga PP, Stefoni V, Tani M, Musuraca G, Marchi E, Falini B, Baccarani M, Pileri SA.
    Haematologica; 2005 Mar; 90(3):341-7. PubMed ID: 15749666
    [Abstract] [Full Text] [Related]

  • 2. Clinicopathologic significance of immunophenotypic profiles related to germinal center and activation B-cell differentiation in diffuse large B-cell lymphoma from Chinese patients.
    Liu YH, Xu FP, Zhuang HG, Lai KC, Xie D, Luo DL, Li L, Luo XL, Xu J, Zhang MH, Zhang F, Li HM.
    Hum Pathol; 2008 Jun; 39(6):875-84. PubMed ID: 18440593
    [Abstract] [Full Text] [Related]

  • 3. Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study.
    Linderoth J, Jerkeman M, Cavallin-Ståhl E, Kvaløy S, Torlakovic E, Nordic Lymphoma Group Study.
    Clin Cancer Res; 2003 Feb; 9(2):722-8. PubMed ID: 12576441
    [Abstract] [Full Text] [Related]

  • 4. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma.
    Muris JJ, Meijer CJ, Vos W, van Krieken JH, Jiwa NM, Ossenkoppele GJ, Oudejans JJ.
    J Pathol; 2006 Apr; 208(5):714-23. PubMed ID: 16400625
    [Abstract] [Full Text] [Related]

  • 5. Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.
    Nyman H, Jerkeman M, Karjalainen-Lindsberg ML, Banham AH, Enblad G, Leppä S.
    Eur J Haematol; 2009 May; 82(5):364-72. PubMed ID: 19141121
    [Abstract] [Full Text] [Related]

  • 6. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement.
    Le Gouill S, Talmant P, Touzeau C, Moreau A, Garand R, Juge-Morineau N, Gaillard F, Gastinne T, Milpied N, Moreau P, Harousseau JL, Avet-Loiseau H.
    Haematologica; 2007 Oct; 92(10):1335-42. PubMed ID: 18024371
    [Abstract] [Full Text] [Related]

  • 7. CD10 and Bcl-2 expression combined with the International Prognostic Index can identify subgroups of patients with diffuse large-cell lymphoma with very good or very poor prognoses.
    Biasoli I, Morais JC, Scheliga A, Milito CB, Romano S, Land M, Pulcheri W, Spector N.
    Histopathology; 2005 Mar; 46(3):328-33. PubMed ID: 15720419
    [Abstract] [Full Text] [Related]

  • 8. Serum levels of inflammatory cytokines at diagnosis correlate to the bcl-6 and CD10 defined germinal centre (GC) phenotype and bcl-2 expression in patients with diffuse large B-cell lymphoma.
    Pedersen LM, Jürgensen GW, Johnsen HE.
    Br J Haematol; 2005 Mar; 128(6):813-9. PubMed ID: 15755285
    [Abstract] [Full Text] [Related]

  • 9. De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients.
    Yamaguchi M, Nakamura N, Suzuki R, Kagami Y, Okamoto M, Ichinohasama R, Yoshino T, Suzumiya J, Murase T, Miura I, Ohshima K, Nishikori M, Tamaru J, Taniwaki M, Hirano M, Morishima Y, Ueda R, Shiku H, Nakamura S.
    Haematologica; 2008 Aug; 93(8):1195-202. PubMed ID: 18556402
    [Abstract] [Full Text] [Related]

  • 10. Prognostic significance of bcl-2, bax, and p53 expression in diffuse large B-cell lymphoma.
    Sohn SK, Jung JT, Kim DH, Kim JG, Kwak EK, Park Ti, Shin DG, Sohn KR, Lee KB.
    Am J Hematol; 2003 Jun; 73(2):101-7. PubMed ID: 12749011
    [Abstract] [Full Text] [Related]

  • 11. Clinicopathologic analysis of CD10+ and CD10- diffuse large B-cell lymphoma. Identification of a high-risk subset with coexpression of CD10 and bcl-2.
    Xu Y, McKenna RW, Molberg KH, Kroft SH.
    Am J Clin Pathol; 2001 Aug; 116(2):183-90. PubMed ID: 11488064
    [Abstract] [Full Text] [Related]

  • 12. Tissue microarray is inappropriate for analysis of BCL6 expression in diffuse large B-cell lymphoma.
    Linderoth J, Ehinger M, Akerman M, Cavallin-Ståhl E, Enblad G, Erlanson M, Jerkeman M.
    Eur J Haematol; 2007 Aug; 79(2):146-9. PubMed ID: 17635238
    [Abstract] [Full Text] [Related]

  • 13. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin.
    López-Guillermo A, Colomo L, Jiménez M, Bosch F, Villamor N, Arenillas L, Muntañola A, Montoto S, Giné E, Colomer D, Beà S, Campo E, Montserrat E.
    J Clin Oncol; 2005 Apr 20; 23(12):2797-804. PubMed ID: 15728226
    [Abstract] [Full Text] [Related]

  • 14. [Large-cell diffuse B-cell lymphoma: heterogenous origin and prognosis from the aspect of modern diagnosis].
    Soukup J, Krsková L, Mrhalová M, Kodet R, Campr V, Kubácková K, Trnĕný M.
    Cas Lek Cesk; 2003 Apr 20; 142(7):417-22. PubMed ID: 14515445
    [Abstract] [Full Text] [Related]

  • 15. Prognostic significance of Fas (CD95/APO-1) positivity in patients with primary nodal diffuse large B-cell lymphoma.
    Eser B, Sari I, Canoz O, Altuntas F, Cakmak E, Ozturk A, Ozkan M, Er O, Cetin M, Unal A.
    Am J Hematol; 2006 May 20; 81(5):307-14. PubMed ID: 16628716
    [Abstract] [Full Text] [Related]

  • 16. Germinal center and activated b-cell profiles separate Burkitt lymphoma and diffuse large B-cell lymphoma in AIDS and non-AIDS cases.
    Gormley RP, Madan R, Dulau AE, Xu D, Tamas EF, Bhattacharyya PK, LeValley A, Xue X, Kumar P, Sparano J, Ramesh KH, Pulijaal V, Cannizzaro L, Walsh D, Ioachim HL, Ratech H.
    Am J Clin Pathol; 2005 Nov 20; 124(5):790-8. PubMed ID: 16203284
    [Abstract] [Full Text] [Related]

  • 17. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma.
    Colomo L, López-Guillermo A, Perales M, Rives S, Martínez A, Bosch F, Colomer D, Falini B, Montserrat E, Campo E.
    Blood; 2003 Jan 01; 101(1):78-84. PubMed ID: 12393466
    [Abstract] [Full Text] [Related]

  • 18. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays.
    Campo E, Mason DY.
    Haematologica; 2005 Mar 01; 90(3):292. PubMed ID: 15749656
    [No Abstract] [Full Text] [Related]

  • 19. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
    Fu K, Weisenburger DD, Choi WW, Perry KD, Smith LM, Shi X, Hans CP, Greiner TC, Bierman PJ, Bociek RG, Armitage JO, Chan WC, Vose JM.
    J Clin Oncol; 2008 Oct 01; 26(28):4587-94. PubMed ID: 18662967
    [Abstract] [Full Text] [Related]

  • 20. Diffuse large B-cell lymphoma: clinical characterization and prognosis of Waldeyer ring versus lymph node presentation.
    Qi SN, Li YX, Wang H, Wang WH, Jin J, Song YW, Wang SL, Liu YP, Zhou LQ, Yu ZH.
    Cancer; 2009 Nov 01; 115(21):4980-9. PubMed ID: 19634158
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.